Global Positron Emission Tomography (PET) Nuclear Medicine Market Trends and Future Outlook to 2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Are The Market Size Estimates For The Positron Emission Tomography (PET) Nuclear Medicine Market?
The market size of the positron emission tomography (pet) nuclear medicine has seen rapid expansion in the past few years. In terms of value, it is forecasted to climb from $11.49 billion in 2024 to $13.16 billion in 2025, boasting a compound annual growth rate (CAGR) of 14.5%. The surge observed in the historical period can be credited to factors such as the growing occurrence of cardiovascular diseases, higher healthcare expenses, increasing incidence of urological disorders, a rise in the elderly population, and an increased count of hospitals.
The market size for positron emission tomography (PET) nuclear medicine is projected to experience significant growth in the upcoming years, expanding to $22.52 billion in 2029 with a compound annual growth rate (CAGR) of 14.4%. The anticipated growth during the forecast period is mainly due to increased investment in research and development, a growing requirement for minimally invasive diagnostic techniques, improvements in global healthcare infrastructure, elevated demand for food and pharmaceutical packaging, and an increased occurrence of cancer. Notable trends for the predicted period comprise technological progression, multi-modality diagnosis, the incorporation of artificial intelligence, digital PET systems, and personalized medicine.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19151&type=smp
What Drivers Are Accelerating Expansion Of The Positron Emission Tomography (PET) Nuclear Medicine Market?
The positron emission tomography (PET) nuclear medicine market is predicted to grow due to the rising incidence of chronic diseases. Long-lasting, often requiring continuous medical care and potentially restricting daily living, chronic diseases commonly last for three or more months. This surge in chronic conditions is fueled by factors including an aging population, insufficient physical exercise, poor dietary habits, and environmental dangers. PET nuclear medicine contributes to chronic disease management by providing sophisticated imaging techniques that facilitate early recognition, accurate diagnosis, and regular monitoring of these conditions. For example, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported around 20 million new instances of cancer and 9.7 million cancer-related deaths in 2022, in February 2024. Furthermore, it is expected that by 2050, new cancer instances will surpass 35 million, a 77% increase from the 2022 figure. Therefore, the escalating incidence of chronic diseases is fueling the growth of the positron emission tomography (PET) nuclear medicine market.
What Are The Key Segment Trends Observed In The Positron Emission Tomography (PET) Nuclear Medicine Market?
The positron emission tomography (pet) nuclear medicinemarket covered in this report is segmented –
1) By Type: F-18; Rb-82; Other Types
2) By Procedure: Diagnostic Procedures; Single Photon Emission Computed Tomography Procedures; Positron Emission Tomography Procedures; Therapeutic Procedures; Beta Emitter Procedures; Alpha Emitter Procedures; Brachytherapy Procedures
3) By Application: Oncology; Cardiology; Neurology; Other Applications
4) By End User: Hospitals; Diagnostic Centers; Research Institutes
Subsegments:
1) By F-18 (Fluorine-18): F-18 FDG (Fluorodeoxyglucose); F-18 NaF (Sodium Fluoride); F-18 Fluorocholine
2) By Rb-82 (Rubidium-82): Rb-82 for Myocardial Perfusion Imaging; Rb-82 for Cardiac PET Stress Testing; Rb-82 for Other Cardiac Applications
3) By Other Types: C-11 (Carbon-11); N-13 (Nitrogen-13); O-15 (Oxygen-15); Ga-68 (Gallium-68)
Which Long-Term Trends Will Play A Crucial Role In The Positron Emission Tomography (PET) Nuclear Medicine Market?
Leading entities within the positron emission tomography (PET) nuclear medicine industry are innovating products with superior technology, like PET slice scanners, in order to provide clear, high-resolution imagery of metabolic activity. PET slice scanners are essentially medical imaging tools which leverage advanced computation techniques and PET to generate detailed, layered imagery of metabolic mechanisms within the body. This greatly assists in the identification and monitoring of diseases, especially cancer. To illustrate, in July 2024, Positron Corporation, an American nuclear medicine firm, rolled out the NeuSight PET-CT 3D 64-slice scanner. This product ushers in a new era in imaging and diagnostic accuracy, fusing cutting-edge technology with patient comfort and operational efficacy. It’s specifically designed to revolutionize cardiac PET imagery and provides remarkable value and performance at an unparalleled price point, marking it as the perfect choice for cardiology and oncology clinical research. Equipped with advanced data capture and innovative identification capacities, the NeuSight PET-CT boosts the scanning speed and precision, resulting in extensive anatomic and functional imaging for heart, tumour, and brain examinations across a range of molecular imaging applications.
Who Are The Major Stakeholders Operating In The Positron Emission Tomography (PET) Nuclear Medicine Market?
Major companies operating in the positron emission tomography (PET) nuclear medicine marker are Cardinal Health, Bayer AG, Medtronic plc, Siemens Healthineers AG, Fujifilm Holdings Corporation, Stryker Corporation, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Agfa HealthCare NV, Scripps Health, Shimadzu Corporation, Jubilant DraxImage Inc., Neusoft Medical Systems Co. Ltd., Toshiba America Medical Systems Inc., Lantheus Holdings Inc., Advanced Accelerator Applications, Bruker Corporation, Eckert & Ziegler Strahlen- und Medizintechnik AG, Canon Medical Systems Corporation, Digirad Corporation, NorthStar Medical Radioisotopes LLC, Mediso Medical Imaging Systems Ltd.
Access The Complete Report Here:
What Regional Factors Are Accelerating Growth In The Positron Emission Tomography (PET) Nuclear Medicine Market?
North America was the largest region in the positron emission tomography (PET) nuclear medicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (PET) nuclear medicine marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=19151&type=smp
Browse Through More Reports Similar to the Global Positron Emission Tomography (PET) Nuclear Medicine Market 2025, By The Business Research Company
Positron Emission Tomography Pet Scanners Global Market Report 2025
Single Photon Emission Computed Tomography Spect Global Market Report 2025
Nuclear Medicine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
